Table 1B.
Endocrinological and Immunological Tests on Admission.
| TSH | 2.22 | μIU/mL | (0.35-4.94) | FACS analysis: | |||
| FT3 | 2.25 | pg/mL | (1.71-3.71) | CD3+T-cell | 69.1 | % | (75-85) |
| FT4 | 1.52 | ng/dL | (0.70-1.55) | CD19+B-cell | 11.8 | % | (5-15) |
| TRAb-3 | <0.9 | IU/mL | (<2.0) | CD4+T-cell | 55.7 | % | (35-55) |
| TgAb | <10.0 | IU/mL | (<28.0) | CD8+T-cell | 11.2 | % | (19-37) |
| TPOAb | <5.0 | U/mL | (<16.0) | CD4/CD8 | 4.97 | (1-1.5) | |
| Cortisol | 16.9 | μg/dL | (2.9-19.4) | ||||
| ACTH | 18.5 | pg/mL | (7.2-63.3) | Th1 | 25.1 | % | |
| PRA | 3.9 | ng/mL/h | (0.2-2.7) | Th2 | 2.9 | % | |
| PAC | 15.6 | pg/mL | (3.6-24) | Th1/Th2 | 8.7 | ||
| GH | 0.1 | ng/mL | (0-2.1) | CD4+CD25+ | 11.9 | % | (6.0-21.0) |
| IGF-I | 51 | ng/mL | (49-158) | CD4- CD25+ | 3.3 | % | (2.0-14.0) |
| LH | 33.1 | mIU/mL | (1.7-11.2) | CD4+CD25- | 48.6 | % | (15.0-39.0) |
| FSH | 122.6 | mIU/mL | (2.1-18.6) | CD4- CD25- | 36.2 | % | (37.0-69.0) |
| E2 | <5 | pg/mL | (<10) | ||||
| P4 | 0.2 | ng/mL | (0.1-0.8) | ||||
| PRL | 14.3 | ng/mL | (<15) | ||||
| ADH | 1.1 | pg/mL | (0.3-4.2) | ||||
| HLA-typing analysis: | |||||||
| HLA-A11, A26 | |||||||
| HLA-B61 | |||||||
| HLA-DR4, DR12 | |||||||
Footnotes: underline denote abnormal values.
TSH: thyrotropin, FT3: triiodothyronine, FT4: thyroxine, TRAb-3: TSH receptor antibody (third generation), TgAb: anti-thyroglobulin antibody, TPOAb: anti-thyroid peroxidase antibody, ACTH: adrenocorticotropic hormone, PRA: plasma renin activity, PAC: plasma aldosterone concentration, GH: growth hormone, IGF-I: insulin-like growth factor-I, LH: luteinizing hormone, FSH: follicle stimulating hormone, E2: estradiol, P4: progesterone, PRL: prolactin, ADH: antidiuretic hormone